Research Paper Volume 15, Issue 17 pp 9217—9229

Figure 1. Protective effect of EFL1 in mice underwent breast cancer-surgical hepatic implantation (SHI). (A, B) Serum levels of liver enzymes aspartate aminotransferase. (AST) and alanine aminotransferase (ALT) were determined using commercial kits. n = 6. (C) Abdominal circumference from surgical hepatic implantation (SHI) mice after 2 weeks of EFL treatment. n = 9. (D) Peritoneal fluid volume was measured after 2 weeks of EFL1 treatment. n = 9. (E) Representative images of liver metastasis and mesenteric re-metastasis in SHI mice. White arrows denote SHI tumor and red arrows denote mesenteric re-metastasis. (F) Representative images of tumor growth in mice received SHI. (G) Body weights recorded right before SHI surgery (Time A) and after 2 weeks of EFL1 administration (Time B). n = 9. (H) Liver tumor weight at the end of the experiment. n = 9. (I) Liver tumor volume recorded right before SHI surgery (Time A) and after 2 weeks of EFL1 administration (Time B). n = 9. Data were compared using one-way ANOVA with Dunnett’s post hoc (A–D, H) or two-way ANOVA with Tukey’s post hoc (G, I). ^##P < 0.01 vs. Control; ^*P < 0.05, ^**P < 0.01 vs. Model.